Status:
COMPLETED
An Observational Cohort Study to Describe and Compare the Use of Darolutamide, Enzalutamide and Apalutamide and How Well These Work in Men With Non-metastatic Castration-resistant Prostate Cancer (nmCRPC) in Real World Settings
Lead Sponsor:
Bayer
Conditions:
Non-metastatic Castration-resistant Prostate Cancer
Eligibility:
MALE
18+ years
Brief Summary
This is an observational cohort study in men with non-metastatic castration-resistant prostate cancer who received their usual treatment, which is 'Androgen receptor inhibitors' (ARIs) including darol...
Eligibility Criteria
Inclusion
- Men diagnosed with prostate cancer.
- Diagnosis of nmCRPC prior to or within 90 days after the first ARI treatment initiation
- Treatment with Darolutamide, Enzalutamide, or Apalutamide initiated for the first time
- Age ≥ 18 years at treatment start
- At least 6 months of Electro-Medical-Record activity after the treatment start unless the patient died earlier than 6 months.
Exclusion
- Evidence of metastatic disease before or 30 days after treatment start
- Prior history of other primary cancers
Key Trial Info
Start Date :
August 31 2023
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 28 2024
Estimated Enrollment :
1375 Patients enrolled
Trial Details
Trial ID
NCT06013475
Start Date
August 31 2023
End Date
October 28 2024
Last Update
June 12 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Bayer
Whippany, New Jersey, United States, 07981